At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,170 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study
In Brief
A Phase 3 clinical trial evaluating Apixaban and Dalteparin for Venous Thromboembolism. Completed, enrolled 1,170 participants across 127 sites in 11 countries.
Detailed Summary
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
CountriesBelgium, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom, United States
CollaboratorsUniversity Of Perugia
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartApr 2017
Primary CompletionJun 2019
Study CompletionDec 2019
TodayJul 2026
First PostedFeb 7, 2017
Enrollment StartApr 13, 2017
Primary CompletionJun 1, 2019
Study CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.4 years ago
Interventions
Apixabandrug
Tablets
Dalteparindrug
Injections